TipRanks
Advertisement
Advertisement

EVMN Stock Latest News

Evommune announces positive Phase 2a results for EVO301
Company AnnouncementsEvommune announces positive Phase 2a results for EVO301
2d ago
8K
EVMN
Evommune presents Phase 2a PoC data on EVO301 at EADV Congress
PremiumThe Fly
Evommune presents Phase 2a PoC data on EVO301 at EADV Congress
2d ago
EVMN
Evommune Highlights Positive EVO301 Atopic Dermatitis Phase 2a Data
PremiumCompany Announcements
Evommune Highlights Positive EVO301 Atopic Dermatitis Phase 2a Data
9d ago
8K
EVMN
Evommune updates pipeline and market outlook in presentation
PremiumCompany Announcements
Evommune updates pipeline and market outlook in presentation
18d ago
8K
EVMN
Evommune price target lowered to $23 from $28 at Clear Street
PremiumThe Fly
Evommune price target lowered to $23 from $28 at Clear Street
23d ago
EVMN
Evommune price target lowered to $18 from $32 at Raymond James
PremiumThe FlyEvommune price target lowered to $18 from $32 at Raymond James
24d ago
EVMN
Evommune price target lowered to $22 from $28 at Leerink
Premium
The Fly
Evommune price target lowered to $22 from $28 at Leerink
24d ago
EVMN
Evommune price target lowered to $21 from $29 at RBC Capital
Premium
The Fly
Evommune price target lowered to $21 from $29 at RBC Capital
24d ago
EVMN
Evommune Shifts Atopic Dermatitis Focus to EVO301
PremiumCompany Announcements
Evommune Shifts Atopic Dermatitis Focus to EVO301
24d ago
8K
EVMN
Closing Bell Movers: Casey’s down 9% after earnings
PremiumThe Fly
Closing Bell Movers: Casey’s down 9% after earnings
24d ago
TH
STX
Evommune Phase 2b EV0756 trial did not meet primary and secondary endpoints
PremiumThe Fly
Evommune Phase 2b EV0756 trial did not meet primary and secondary endpoints
24d ago
EVMN
Evommune down 31% at $9 after Phase 2b EVO-756 study results
PremiumThe Fly
Evommune down 31% at $9 after Phase 2b EVO-756 study results
24d ago
EVMN
Analyst Initiates Buy on Evommune, Citing Strong EVO301 Proof-of-Concept and Upside Optionality from EVO756
PremiumRatingsAnalyst Initiates Buy on Evommune, Citing Strong EVO301 Proof-of-Concept and Upside Optionality from EVO756
1M ago
EVMN
Evommune initiated with a Buy at Needham
Premium
The Fly
Evommune initiated with a Buy at Needham
1M ago
EVMN
Evommune price target lowered to $29 from $30 at RBC Capital
Premium
The Fly
Evommune price target lowered to $29 from $30 at RBC Capital
2M ago
EVMN
Evommune reports Q2 EPS (89c), consensus (67c)
PremiumThe Fly
Evommune reports Q2 EPS (89c), consensus (67c)
2M ago
EVMN
Evommune Launches Phase 2b Trial for EVO756 Migraine Drug
PremiumCompany Announcements
Evommune Launches Phase 2b Trial for EVO756 Migraine Drug
2M ago
8K
EVMN
Evommune initiates Phase 2b trial of EVO756
PremiumThe Fly
Evommune initiates Phase 2b trial of EVO756
2M ago
EVMN
Evommune participates in a conference call with Cantor
PremiumThe Fly
Evommune participates in a conference call with Cantor
2M ago
EVMN
Clear Street sees attractive point into Evommune after selloff
PremiumThe FlyClear Street sees attractive point into Evommune after selloff
3M ago
EVMN
Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study
Premium
Company Announcements
Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study
3M ago
EVMN
Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market
Premium
Company Announcements
Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market
3M ago
EVMN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >